1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsIndependent Medical Education Grants is sponsored by Genentech. Genentech invests in bold ideas and innovative solutions that address disparities in science and medicine to advance a more inclusive healthcare system.
Get alerted about grants like this
Save a search for “Genentech” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Genentech: Independent Medical Education Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported. Independent Medical Education Independent Medical Education Genentech supports grants for independent medical education in an effort to advance excellence in medicine and healthcare and improve patient health outcomes by enhancing the knowledge of the medical community.
Independent Medical Education (IME) is generally defined as education for healthcare professionals (HCPs) provided by an independent educational provider, such as a community hospital, academic center, society/association or medical education and communication company.
Before you submit an application, we encourage you to explore the following materials to learn more about our opportunities for funding, eligibility requirements and considerations, and the process for submitting a proposal within our system. All aspects related to IME including but not limited to the agenda, content, and faculty, must remain fully independent and be under the sole control of the activity organizers.
Genentech will not provide any guidance to the IME provider. All accredited programs must follow the standards set forth in the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Genentech is actively seeking applications for independent medical education.
Click on the link below for more information and detailed instructions on submitting a Request for Proposal (RFP) application: NEW! Independent Medical Education Request for Proposals - Diffuse Large B-cell Lymphoma What to know and materials to gather before you apply: Grant requests must be submitted at least 60 days prior to the project/program/event start date.
You’ll need the following materials to submit your application: W-9 Form / W-8BEN Form (Please note you will need the most current version of IRS form, signed within one year of application submission) Detailed / Itemized Budget Details for Preferred Payment Method (Electronic vs Check) Identification of Authorized LOA Signer Needs assessment document Funding Requirements & Priorities Requests for funding an accredited continuing education activity must be submitted by the organization accrediting the activity (the accredited provider) NOTE: If there are multiple credit types offered for the activity: The ACCME-accredited organization must submit the application for any activities that offer AMA PRA Category 1 credit for physicians If no AMA PRA Category 1 credit is offered for the activity, then an accredited provider offering a different credit type for the activity is eligible to submit the request Your organization must not be: A political or sectarian organization An individual, group practice, or private physician office If your organization is an accredited provider but you will be utilizing a non-accredited third party implementation provider to implement the proposed activity: The third-party implementation provider must not be owned in whole or in part by, or controlled by a practicing physician or other HCP, or a group practice of physicians or other HCPs (regardless of size) The third-party implementation provider must not be owned in whole or in part by, or controlled by, an individual who is an immediate family member of a practicing physician or other HCP Organizations which also perform promotional activities must have sufficient separation (firewalls) between the grant requestor's or partner's promotional and medical education business units.
Learn more about Genentech's firewall requirements via the dropdown below. What constitutes a proper medical education firewall?
Genentech prohibits grant requestors and their educational partners (e.g., third party providers) from performing promotional activities for Genentech while also contributing to, providing or accrediting independent medical education (IME) funded in whole or part by Genentech, unless there is sufficient separation (firewalls) between the grant requestor's or partner's promotional and medical education business units.
Before a grant request is considered, the grant requestor must certify to Genentech that it and all its educational partners adhere to a firewall policy that is in compliance with Genentech's firewall criteria, an overview of which may be found below. All requestors must complete a Firewall Certification Form when registering online with Genentech's Funding Request System and must re-certify compliance annually.
Separate Employees/Contractors Separation of promotional/IME information and content, including, but not limited to, prohibition on sharing substantive information, physical separation of functions, and information technology (IT) safeguards Compliance training and audits Monitoring of compliance policies and corrective action In order to be eligible, the funding must not be used for: The purpose of developing clinical practice guidelines, e.g., statements that include recommendations intended to help practitioners make appropriate health care decisions for specific clinical conditions Support a religious purpose Promotion of a Genentech or Roche product or to influence formulary decisions Travel, lodging or registration expenses for non-faculty healthcare professionals to attend an educational program (there are certain exceptions for healthcare professionals in training: i.e. medical students, fellows, etc. to attend major medical society meetings) Operating expenses that are not directly and exclusively dedicated to the educational activity being applied for (e.g. equipment, salaries, benefits, journal subscriptions, etc.) Support a promotional exhibit or display space/fees (please contact your local Genentech representative regarding requests for exhibit fees) Stand-alone entertainment or social events Staff/professional development Grant requests from applicants who have received past grant funding, but have not provided required reconciliation information or have not returned unused funds Grant requests for programs that take place in a location, venue or in a schedule that detracts from the educational activity as the primary purpose Grant requests that contain unacceptable budget line items, such as: Funding for healthcare professional partners or guests Faculty lodging and/or expense reimbursement out of proportion with the number of days that the faculty is presenting Gifts/prizes for faculty or attendees Funding for faculty dinners not related to content review Honoraria or costs in excess of fair market value Genentech/Roche will consider funding requests in the following disease states: Age-Related Macular Degeneration Bladder Cancer, Muscle Invasive HR+/HER2- with PIK3CA -mutations Childhood-onset Idiopathic Nephrotic Syndrome (INS) Chronic Obstructive Pulmonary Disease (COPD) Irritable Bowel Disease (IBD) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Paroxysmal Nocturnal Hemoglobinuria Primary Membranous Nephropathy (MN) Systemic Lupus Erythematosus Funding Process – What to Expect* *Please note the funding process for RFPs may include additional steps.
1. Review Online Resources Click here for video tutorials, one-page tip sheets, and FAQs on how to use the funding request system. 2.
Submit Application via our Funding Request System (gFRS) You will receive a confirmation email upon submission. Your request will be reviewed for alignment to strategic focus areas and compliance with Genentech's policies 4. If Additional Information is Needed If we need more information to make a decision, you will receive a Request for Information (RFI), or hear from a team member directly.
You will be able to track the status of an application and will receive an email communication regarding the final decision. If approved, your organization will need to enter into a Letter of Agreement (LOA) with Genentech in order to receive funds. *Please note that our Funding Request System works best in Chrome and Safari
Based on current listing details, eligibility includes: Legally established healthcare organizations, associations, medical specialty societies, academic institutions, hospitals, and medical education companies. Typically funds US-based programs. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Philanthropic Charitable Support is sponsored by Genentech Patient Foundation. Funding for non-healthcare-related programs focused on humanitarian and social issues, science education, or the community and environment. Requests must be submitted at least 60 days before the project start date. Geographic focus: United States (Priority for South San Francisco, Vacaville, Oceanside, CA; Hillsboro, Portland, OR) Focus areas: Humanitarian Programs, Social Programs, Science Education, Community & Environment
Independent Co-pay Assistance Foundation Charitable Support is a grant from the Genentech Patient Foundation that funds independent charitable foundations providing co-pay assistance to patients who cannot afford out-of-pocket costs for medications. The program is part of Genentech's broader commitment to expanding access to healthcare and reducing disparities in medicine. Eligible applicants must be 501(c)(3), 501(c)(4), or 501(c)(6) organizations with a current, favorable OIG opinion for their co-payment assistance program. Requests are submitted through Genentech's Funding Request System (gFRS), with the portal accepting rolling submissions throughout the year.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.